As it turns out, Amgen (Nasdaq:AMGN) didn't have to stretch too far to seal the deal for oncology biotech company Onyx Pharmaceuticals (Nasdaq:ONXX). While Amgen's initial bid of $120 per Onyx share set off a nearly two-month auction process, in the end it took only an extra $5 per share to complete the deal as there was apparently only passing interest from other Big Pharma players to pay up for Onyx's portfolio of oncology drugs. All in all, while it's a worthwhile deal that helps patch over some near-term growth concerns for Amgen, it's unlikely to be a transformative deal.
 
The Deal
Amgen and Onyx announced that the two companies had reached a definitive agreement by which Amgen will acquire Onyx for $125 per share in cash. At that price, Amgen is paying an enterprise value of just under $10 billion and a premium of over 45% to the share price before word first broke that Onyx was receiving indications of interest.

SEE: What Makes An M&A Deal Work?
 
Amgen will be financing this deal with over $8 billion in bank loans priced at LIBOR plus 104bp. The key drug to the deal, multiple myeloma drug Kyprolis, is already approved by the FDA and the sales of the drug (coupled with cutting redundant expenses at Onyx) should lead to Amgen seeing accretion from the deal in 2015.
 
Advancing The Ball, But Not Changing The Game
While it's possible that Onyx has a hidden gem in preclinical research, this deal looks more like an incremental step forward for Amgen than a transformative deal that will fundamentally change the company's trajectory. In particular, this deal for Onyx will help Amgen get through a challenging growth gap in the 2014-2016 period and better leverage its existing sales and manufacturing infrastructure.

Said differently, Amgen investors should not look at this as a deal on par with Johnson & Johnson's (NYSE:JNJ) acquisition of Cougar or Celgene's (Nasdaq:CELG) acquisition of Abraxis. What's more, while there is potential upside from Onyx's drug palbociclib (licensed to Pfizer (NYSE:PFE)), there are are also risks to Kyprolis from an increasingly competitive myeloma market, including Celgene's portfolio and Phase III drugs from Takeda and Bristol-Myers Squibb (NYSE:BMY).
 
The Bottom Line
All told, I believe Kyprolis can add $7 billion to $8 billion in net value to Amgen (net of the purchase price), assuming that Amgen can strip out at least half of Onyx's non-R&D operating expenses. The remainder of Onyx's portfolio and pipeline (again, excluding any hidden gems in preclinical development) is likely worth around $500 million to $1.5 billion. Relative to a pre-deal enterprise value of $81.5 billion for Amgen, then, this deal is worthwhile and value-additive, but again not a transformative event.
 
Amgen share's jumped 9% in early trading. The company is likely to continue to face pointed questions regarding its ability to leverage past deals, but the company does appear to be following a coherent strategy of lower-risk building block deals.
 
Disclosure – At the time of writing, the author did not own shares of any company mentioned in this article.

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Stock Analysis

    5 Reasons Thoratec Corp. Keeps Impressing Investors

    Learn about Thoratec Corporation and its position in its industry. Understand five key factors why the company has impressed investors.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Weighted Average Cost Of Capital ...

    A calculation of a firm's cost of capital in which each category ...
  3. Runoff Insurance

    An insurance policy provision that provides liability coverage ...
  4. Hunting Elephants

    The practice of targeting large companies or customers.
  5. Precedent Transaction Analysis

    A valuation method in which the prices paid for similar companies ...
  6. Poison Put

    A takeover defense strategy in which the target company issues ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. How long does it take to execute an M&A deal?

    Even the simplest merger and acquisition (M&A) deals are challenging. It takes a lot for two previously independent enterprises ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!